pain

In the Lab By Associated Press

U.S. awards $3 million to fill gaps in medical marijuana research

First Opinion By Dawn Rae Downton

Who is really behind a proposed new definition of pain?

Pharma By David Armstrong — ProPublica

Watch: In never-before-seen video, Purdue’s Richard Sackler defends OxyContin marketing

First Opinion By Tom Bowen

Five things I wish I knew earlier in my journey with chronic pain

Health By Lauren Joseph

Study: 2% of women have ‘persistent’ opioid use after childbirth

Health By Ruth Hailu

‘Sickle cell needs more funding’: An 18-year-old patient advocate calls on Washington to improve children’s health care

Special Report By Julie Appleby and Elizabeth Lucas — Kaiser Health News

While addiction crisis raged, many surgeons overprescribed opioids, analysis shows

Special Report By Kaiser Health News

How the Kaiser-Johns Hopkins analysis was done

First Opinion By Ben Goodwin, Judy Butler, and Adriane Fugh-Berman

Industry-funded attacks on the CDC’s opioid prescribing guideline are eroding public health

First Opinion By William Fleischman and Joseph S. Ross

How Insys undermined an FDA effort to protect the public from dangerous opioids

Biotech By Damian Garde

Disappointing trial results dim hopes for a new class of pain drugs

Biotech By Damian Garde

How one company thinks unraveling cough can provide a new way to treat pain

In the Lab By Jacquelyn Corley

The case of a woman who feels almost no pain leads scientists to a new gene mutation

First Opinion By Dave Chase

The opioid crisis is partly fueled by insurers’ and employers’ approach to back pain

Health By Lev Facher

Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections

Health By Damian Garde

So good it hurts: Why drug makers looking to replace opioids want to keep some pain in the picture

Health By Casey Ross

Once a last resort, this pain therapy is getting a new life amid the opioid crisis

Health By Casey Ross

At glitzy Vegas tech show, chronic-disease gadgets to take center stage

Health By Lev Facher

Kaleo, maker of $4,100 overdose antidote, authorizes a generic version for just $178

The Pharmalot View By Ed Silverman

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

In the Lab By Adam Feuerstein

One to watch at ASH18: She’s 17 and she studies chronic pain in sickle cell disease

First Opinion By Jeffrey Gudin

Now that the SUPPORT Act is law, where do we go from there?

First Opinion By Maia Dolphin-Krute

Viewing the opioid crisis as an ecological disaster could help with ‘cleanup’

Health By Lev Facher

Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids

First Opinion By Ken Gordon

What Philip Roth’s ‘The Anatomy Lesson’ can teach us about pain and addiction